Review Reports
- Anastasia Chambers,
- Morgan Reeves and
- Ali Zarrinpar *
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous Reviewer 3: Rie Sugimoto
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThis manuscript presents a comprehensive review of β-catenin signaling in hepatocellular carcinoma (HCC), with emphasis on its role in therapeutic resistance and emerging treatment strategies. The topic is timely and clinically relevant, as β-catenin represents one of the most frequently altered pathways in HCC cases and acts as a major barrier to effective therapy. The manuscript is generally well structured, with extensive literature coverage, and provides a logical framework for understanding how aberrant β-catenin signaling contributes to chemotherapy resistance, targeted therapy failure, and immunotherapy evasion. However, some points should be addressed before the manuscript can be acceptable for publication, including:
- The authors should add a table comparing the different therapeutic strategies targeting β-catenin signaling, including their mechanisms, advantages, and limitations.
- A section discussing clinically applicable biomarkers for patient selection would strengthen the translational value of the review. In addition to CTNNB1 mutations, the authors should discuss biomarkers such as β-catenin nuclear localization, glutamine synthetase expression, and other potential predictive biomarkers that may help identify patients likely to benefit from β-catenin-targeted therapies.
- Throughout the manuscript, there is inconsistency in the use of "β-catenin" versus "beta-catenin" and "CTNNB1" versus "CTNNB1". The authors should standardize the terminology.
- The manuscript contains an inconsistency in section numbering. Section 2.2 is followed by subsections labeled 2.1.1, 2.1.2, and 2.1.3. The numbering should be revised throughout the manuscript.
Author Response
This manuscript presents a comprehensive review of β-catenin signaling in hepatocellular carcinoma (HCC), with emphasis on its role in therapeutic resistance and emerging treatment strategies. The topic is timely and clinically relevant, as β-catenin represents one of the most frequently altered pathways in HCC cases and acts as a major barrier to effective therapy. The manuscript is generally well structured, with extensive literature coverage, and provides a logical framework for understanding how aberrant β-catenin signaling contributes to chemotherapy resistance, targeted therapy failure, and immunotherapy evasion. However, some points should be addressed before the manuscript can be acceptable for publication, including:
Response: Thank you for your review of our article. We appreciate your feedback and have taken your suggestions and made the following revisions below.
- The authors should add a table comparing the different therapeutic strategies targeting β-catenin signaling, including their mechanisms, advantages, and limitations.
Response: Thank you for highlighting this. We agree that the addition of a table summarizing the therapies discussed in the text would be a helpful contribution to the paper. Therefore, we have added Table 1 (page 16, line 663) to section 4 (therapeutic strategies targeting β-catenin in HCC).
- A section discussing clinically applicable biomarkers for patient selection would strengthen the translational value of the review. In addition to CTNNB1 mutations, the authors should discuss biomarkers such as β-catenin nuclear localization, glutamine synthetase expression, and other potential predictive biomarkers that may help identify patients likely to benefit from β-catenin-targeted therapies.
Response: Thank you for pointing this out. We have added a section to highlight how biomarkers for β-catenin active tumors can be used in selection of therapeutic strategy. To see the addition go to page 21, section 4.E (lines 887-981). We highlighted techniques like nuclear β-catenin localization, glutamine synthase expression, genome profiling, molecular profiling, and EOB-MRI.
- Throughout the manuscript, there is inconsistency in the use of "β-catenin" versus "beta-catenin" and "CTNNB1" versus "CTNNB1". The authors should standardize the terminology.
Response: Agreed. We have revised the document accordingly. All statements regarding the protein use the Greek symbol form of the name, β-catenin, and all gene abbreviations are italicized, CTNNB1.
- The manuscript contains an inconsistency in section numbering. Section 2.2 is followed by subsections labeled 2.1.1, 2.1.2, and 2.1.3. The numbering should be revised throughout the manuscript.
Response: Agreed. We have revised the document accordingly. All sections are now numbered correctly and with consistent formatting.
Reviewer 2 Report
Comments and Suggestions for AuthorsThis review provides a comprehensive overview of the role of β-catenin signaling in hepatocellular carcinoma (HCC), with particular emphasis on mechanisms of therapeutic resistance and emerging therapeutic strategies. The topic is timely and clinically relevant, especially given the increasing use of targeted therapies and immune checkpoint inhibitors in HCC. The manuscript is generally well organized and supported by an extensive literature review. However, the review remains largely descriptive and would benefit from a more critical discussion of the literature, improved integration of emerging concepts, and clarification of several scientific and structural issues before publication.
Major Comments:
- The manuscript mainly summarizes published studies but does not really engage with the strength of the evidence or conflicting findings. For a high-impact review, it would be important to discuss controversies, study limitations, and unanswered questions rather than presenting the field as if the literature were fully consistent.
- The review focuses almost entirely on canonical Wnt/β-catenin signaling. A short discussion of non-canonical Wnt pathways, such as Wnt5a, PCP, and Ca²⁺ signaling, as well as how they interact with canonical signaling, would make the overview more complete.
- Although CTNNB1 mutation status is mentioned repeatedly, there is limited discussion of clinically useful biomarkers such as nuclear β-catenin localization, glutamine synthetase staining, transcriptional signatures, immune-excluded phenotypes, and circulating biomarkers. Adding a section on clinical biomarkers would improve the translational relevance of the review.
- The therapy section places a strong emphasis on preclinical approaches but gives much less attention to failed clinical trials, toxicity associated with Wnt inhibition, on-target adverse effects, pharmacokinetic limitations, and the challenges of systemic β-catenin inhibition. A more balanced discussion of these issues is needed. A table summarizing whether clinical trials have failed, are ongoing, or have been completed would also strengthen the translational aspect of the review.
- Immune exclusion is discussed in detail, but other important stromal components, including hepatic stellate cells, cancer-associated fibroblasts, endothelial cells, ECM remodeling, and fibrosis-related signaling, are largely missing despite their relevance to β-catenin signaling.
- The manuscript gives little attention to recent advances such as single-cell RNA sequencing, spatial transcriptomics, spatial proteomics, multiomics, CRISPR functional screens, and AI-based molecular classification, all of which have helped advance the field of β-catenin-driven HCC.
- The manuscript gives little attention to recent advances such as single-cell RNA sequencing, spatial transcriptomics, spatial proteomics, multiomics, CRISPR functional screens, and AI-based molecular classification, all of which have helped advance the field of β-catenin-driven HCC.
Minor comments:
- Several subsection headings still contain drafting placeholders such as “A:”, “B:”, and “C:”. These should be removed before publication.
- Some sections are longer than necessary and would be easier to read if broken into smaller paragraphs.
- Several claims about therapeutic efficacy are stated too strongly given that they are supported only by preclinical data. More cautious wording would be more appropriate in those places.
- The figures are useful, but they could be improved by adding visuals for canonical versus non-canonical Wnt signaling, tumor microenvironment interactions, biomarker-guided therapeutic strategies, and mechanisms of immune exclusion. This would make the review clearer and reduce the amount of explanatory text needed.
- Figure legends should define all abbreviations clearly and distinguish activation, inhibition, direct interactions, and indirect regulatory effects more explicitly.
- Minor grammatical inconsistencies, punctuation issues, and occasional awkward phrasing should be corrected during language editing.
Author Response
This review provides a comprehensive overview of the role of β-catenin signaling in hepatocellular carcinoma (HCC), with particular emphasis on mechanisms of therapeutic resistance and emerging therapeutic strategies. The topic is timely and clinically relevant, especially given the increasing use of targeted therapies and immune checkpoint inhibitors in HCC. The manuscript is generally well organized and supported by an extensive literature review. However, the review remains largely descriptive and would benefit from a more critical discussion of the literature, improved integration of emerging concepts, and clarification of several scientific and structural issues before publication.
Response: Thank you for your time and feedback. We have worked to address your concerns and added more critical discussion of the literature, limitations, and emerging concepts.
Major Comments:
- The manuscript mainly summarizes published studies but does not really engage with the strength of the evidence or conflicting findings. For a high-impact review, it would be important to discuss controversies, study limitations, and unanswered questions rather than presenting the field as if the literature were fully consistent.
Response: Thank you for highlighting this. Corrections to the language and some additions to the text were made throughout to further discuss controversies, study limitations, and unanswered questions. Please see sections in red for these additions.
- The review focuses almost entirely on canonical Wnt/β-catenin signaling. A short discussion of non-canonical Wnt pathways, such as Wnt5a, PCP, and Ca²⁺ signaling, as well as how they interact with canonical signaling, would make the overview more complete.
Response: Agreed. We have modified the text to include discussion of the non-canonical signaling pathway and its crosstalk with the canonical signaling pathway. Please see section 1.C paragraph 3 and 4 (page 5, lines 175-190).
- Although CTNNB1 mutation status is mentioned repeatedly, there is limited discussion of clinically useful biomarkers such as nuclear β-catenin localization, glutamine synthetase staining, transcriptional signatures, immune-excluded phenotypes, and circulating biomarkers. Adding a section on clinical biomarkers would improve the translational relevance of the review.
Response: Thank you for pointing this out. We have added a section to highlight how biomarkers for β-catenin active tumors can be used in selection of therapeutic strategy. To see the addition go to page 21, section 4.E (lines 887-981). We highlighted techniques like nuclear β-catenin localization, glutamine synthase expression, genome profiling, molecular profiling, and EOB-MRI.
- The therapy section places a strong emphasis on preclinical approaches but gives much less attention to failed clinical trials, toxicity associated with Wnt inhibition, on-target adverse effects, pharmacokinetic limitations, and the challenges of systemic β-catenin inhibition. A more balanced discussion of these issues is needed. A table summarizing whether clinical trials have failed, are ongoing, or have been completed would also strengthen the translational aspect of the review.
Response: Agreed. Thank you for pointing this out. We have addressed this by adding a section to the text and a Table summarizing these clinical trials, their findings, and their limitations. To find these additions please see section 4.F “Clinical translation and limitations of systemic Wnt/β-catenin inhibition” (page 23, lines 983-1062).
- Immune exclusion is discussed in detail, but other important stromal components, including hepatic stellate cells, cancer-associated fibroblasts, endothelial cells, ECM remodeling, and fibrosis-related signaling, are largely missing despite their relevance to β-catenin signaling.
Response: Thank you for highlighting this gap. We have modified the text to now discuss how β-catenin signaling is shaped by non-immune stromal components. Please see section 2.C.2 “Context-dependent” paragraph 4 (page 10-11, lines 437-448).
- The manuscript gives little attention to recent advances such as single-cell RNA sequencing, spatial transcriptomics, spatial proteomics, multiomics, CRISPR functional screens, and AI-based molecular classification, all of which have helped advance the field of β-catenin-driven HCC.
Response: Thank you for highlighting this. We have chosen to address this gap by discussing how these technologies have shaped the field of β-catenin-driven tumor characterization and selection of therapeutic strategy. To see the addition go to page 21, section 4.E (lines 887-981).
- The manuscript gives little attention to recent advances such as single-cell RNA sequencing, spatial transcriptomics, spatial proteomics, multiomics, CRISPR functional screens, and AI-based molecular classification, all of which have helped advance the field of β-catenin-driven HCC.
Response: Please see above response.
Minor comments:
- Several subsection headings still contain drafting placeholders such as “A:”, “B:”, and “C:”. These should be removed before publication.
Response: Agreed. We have updated the subsection headings accordingly.
- Some sections are longer than necessary and would be easier to read if broken into smaller paragraphs.
Response: Agreed. We have updated the text by breaking sections up further into subsections.
- Several claims about therapeutic efficacy are stated too strongly given that they are supported only by preclinical data. More cautious wording would be more appropriate in those places.
Response: Thank you for bringing this to our attention. We have made changes in the language to make statements more reflective of findings and have included more discussion of clinical data and limitations.
- The figures are useful, but they could be improved by adding visuals for canonical versus non-canonical Wnt signaling, tumor microenvironment interactions, biomarker-guided therapeutic strategies, and mechanisms of immune exclusion. This would make the review clearer and reduce the amount of explanatory text needed.
Response: Thank you for pointing this out. To address this, we have made some of the following choices. A section of text was added to discuss canonical vs non-canonical signaling and crosstalk. Tumor microenvironment interactions and mechanisms of immune exclusion are discussed in the text and briefly referenced in Figure 2. A section was added to address biomarker-guided therapeutic strategies. We decided against addition of these texts as subsequent figures due to length of paper and number of figures and tables already included to summarize the text.
- Figure legends should define all abbreviations clearly and distinguish activation, inhibition, direct interactions, and indirect regulatory effects more explicitly.
Response: Agreed. We have revised figure legends to include definitions of abbreviations and discuss all symbols used more explicitly.
Comments on the Quality of English Language
- Minor grammatical inconsistencies, punctuation issues, and occasional awkward phrasing should be corrected during language editing.
Response: Thank you for your feedback. We have gone through and reread the text and made changes to make the writing more clear and less awkward.
Reviewer 3 Report
Comments and Suggestions for AuthorsMajor Revision
Although this paper makes no mention whatsoever of the relationship between β-catenin mutations and EOB-MRI, as this is likely to be a crucial factor in formulating treatment strategies for hepatocellular carcinoma involving β-catenin mutations, I would very much like this point to be addressed.
The structure of the text is somewhat unclear. Currently, immune checkpoint inhibitor (ICI) therapy is considered the first-line treatment for hepatocellular carcinoma, whilst molecularly targeted drugs are reserved for second-line treatment and beyond. It would appear that the aspects most characteristic of and significant in relation to β-catenin mutations in hepatocellular carcinoma are the effects on the Tumor Microenvironment and Immune Consequences, as outlined in section 2.1.4, and the sections 3.4.1 to 3.4.3; however, as all these points are discussed in parallel within section 3.3, the focus is not sufficiently narrowed, making the text difficult to understand. It would likely aid the reader’s understanding if the text were written with a slightly greater emphasis on immune checkpoint inhibitors.
With regard to 1.2.B, it is not appropriate to list retrospective studies without citing papers with a high level of evidence in the overview of current treatments for hepatocellular carcinoma. As for nivolumab plus ipilimumab, it is now recognised as a first-line treatment for hepatocellular carcinoma, based on the paper by Yau T et al. published in *The Lancet* in 2025.
Author Response
Although this paper makes no mention whatsoever of the relationship between β-catenin mutations and EOB-MRI, as this is likely to be a crucial factor in formulating treatment strategies for hepatocellular carcinoma involving β-catenin mutations, I would very much like this point to be addressed.
The structure of the text is somewhat unclear. Currently, immune checkpoint inhibitor (ICI) therapy is considered the first-line treatment for hepatocellular carcinoma, whilst molecularly targeted drugs are reserved for second-line treatment and beyond. It would appear that the aspects most characteristic of and significant in relation to β-catenin mutations in hepatocellular carcinoma are the effects on the Tumor Microenvironment and Immune Consequences, as outlined in section 2.1.4, and the sections 3.4.1 to 3.4.3; however, as all these points are discussed in parallel within section 3.3, the focus is not sufficiently narrowed, making the text difficult to understand. It would likely aid the reader’s understanding if the text were written with a slightly greater emphasis on immune checkpoint inhibitors.
With regard to 1.2.B, it is not appropriate to list retrospective studies without citing papers with a high level of evidence in the overview of current treatments for hepatocellular carcinoma. As for nivolumab plus ipilimumab, it is now recognised as a first-line treatment for hepatocellular carcinoma, based on the paper by Yau T et al. published in *The Lancet* in 2025.
Response: Thank you for your review of our paper and feedback. We have made revisions to the article to address your concerns. A section was added to the paper discussion “biomarker-guided β-catenin-directed therapy”, and a subsection was written to discuss the use of the non-invasive biomarker, EOB-MRI (see 4.E.4, lines 957-981). The text mentions how this biomarker can be used as a potential indicator of a tumor being β-catenin active and how that would have implications for selection of therapy. Rewording and additions were made throughout the text to address first vs second line therapies and to place heavier emphasis on immune checkpoint inhibitors. Nivolumab plus ipilimumab are now listed as first line treatment in the text and the updated reference was added (see Section 1.B. page 3, lines 108-110).
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsThe authors have adequately addressed the major concerns raised in the previous review. However, clear and informative legends should be added to the tables.
Author Response
Thank you.
Reviewer 2 Report
Comments and Suggestions for AuthorsThe authors have made substantial changes to the manuscript, and it can now be accepted as is.
Author Response
Thank you
Reviewer 3 Report
Comments and Suggestions for AuthorsThe authors have responded thoroughly to my comments and have properly addressed the issues raised in the paper. The problems have been resolved, and I believe this paper should be accepted.
Author Response
Thank you